

10744 COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY

Honorable Gaylord Nelson

-4-

March 29, 1974

With this single clarification for the word "lincomycin," I believe that all aspects of the testimony I presented were accurate in every respect. Moreover, as you are aware, as enclosures to my letter dated February 25, addressed to you as Subcommittee Chairman, for examination and verification purposes, I supplied the Subcommittee with copies of all the documents referred to in my testimony, including the DFSC purchase specifications pertaining to the articles referred to in Mr. Stetler's letter.

Consequently, while I agree with Mr. Stetler's conclusion "that damaging inferences" could be drawn from my testimony, it is my opinion that these damaging inferences are justified and substantiated. Moreover, it is also my opinion that he has attempted to perpetuate a typical drug industry "snow job" on your Subcommittee in asserting that what I presented constituted "misinformation."

Sincerely,

Edward G. Feldmann, Ph.D.
Associate Executive Director
for Scientific Affairs

EGF:ehb

cc: Mr. John O. Adams, Minority Counsel
Mr. C. Joseph Stetler, PMA